BRIEF-Lilly And Incyte Announce Results From Phase 3 Cov-Barrier Study Of Baricitinib In Hospitalized Covid-19 Patients
BRIEF-Lilly And Incyte Announce Results From Phase 3 Cov-Barrier Study Of Baricitinib In Hospitalized Covid-19 Patients
* LILLY AND INCYTE ANNOUNCE RESULTS FROM THE PHASE 3 COV-BARRIER STUDY OF BARICITINIB IN HOSPITALIZED COVID-19 PATIENTS
* INCYTE CORP - RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF 1,525 PATIENTS DID NOT MEET STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT
* INCYTE - DATA SHOWED 38% REDUCTION IN MORTALITY BY DAY 28 IN PATIENTS TREATED WITH BARICITINIB IN ADDITION TO STANDARD OF CARE
* INCYTE CORP - FREQUENCY OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS WERE GENERALLY SIMILAR IN BARICITINIB AND PLACEBO GROUPS
* INCYTE CORP - NO NEW SAFETY SIGNALS POTENTIALLY RELATED TO USE OF BARICITINIB WERE IDENTIFIED
* INCYTE CORP - TRIAL SHOWED LARGEST EFFECT REPORTED TO DATE FOR REDUCTION IN MORTALITY OBSERVED FOR THIS CERTAIN PATIENT POPULATION WITH COVID-19
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
April 8 (Reuters) - Incyte Corp :
* LILLY AND INCYTE ANNOUNCE RESULTS FROM THE PHASE 3 COV-BARRIER STUDY OF BARICITINIB IN HOSPITALIZED COVID-19 PATIENTS
* INCYTE CORP - RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF 1,525 PATIENTS DID NOT MEET STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT
* INCYTE - DATA SHOWED 38% REDUCTION IN MORTALITY BY DAY 28 IN PATIENTS TREATED WITH BARICITINIB IN ADDITION TO STANDARD OF CARE
* INCYTE CORP - FREQUENCY OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS WERE GENERALLY SIMILAR IN BARICITINIB AND PLACEBO GROUPS
* INCYTE CORP - NO NEW SAFETY SIGNALS POTENTIALLY RELATED TO USE OF BARICITINIB WERE IDENTIFIED
* INCYTE CORP - TRIAL SHOWED LARGEST EFFECT REPORTED TO DATE FOR REDUCTION IN MORTALITY OBSERVED FOR THIS CERTAIN PATIENT POPULATION WITH COVID-19
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透4月8日電-Incell Corp:*禮來公司和Incell公司宣佈在住院的新冠肺炎患者中進行巴利替尼的3期COV屏障研究的結果*Incell Corp-對1,525名患者進行的隨機、雙盲、安慰劑對照研究,在主要終點上不符合統計學意義*Incell-數據顯示,除標準護理外,接受巴利替尼治療的患者到第28天死亡率降低38%*Incell Corp-巴利西尼組和安慰劑組不良事件和嚴重不良事件的頻率大致相似*Incell Corp-沒有發現可能與使用巴利西尼有關的新安全信號*Incell Corp-試驗顯示,迄今為止報道的對使用新冠肺炎的這一特定患者羣體的死亡率降低的最大效果Eikon的源文本:進一步的公司報道:(Reurs.Briefs@thomsonreurs.com;)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧